Acute Chest Syndrome
24
3
3
12
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
3 terminated out of 24 trials
80.0%
-6.5% vs benchmark
13%
3 trials in Phase 3/4
33%
4 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (24)
Ultrasound Acute Chest Syndrome Sickle Cell Disease
Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care
Daily Vitamin D for Sickle-cell Respiratory Complications
Awake Prone Positioning for Severe Acute Chest Syndrome
Use of Macrolides in Acute Chest Syndrome: A Multicenter Retrospective Study
Tocilizumab for Acute Chest Syndrome
Combined Use of a Respiratory Broad Panel Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Hospitalized Sickle-cell Adults With Acute Chest Syndrome.
Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
Vitamin D for Sickle-cell Respiratory Complications
Therapeutic Anticoagulation Strategy for Acute Chest Syndrome
Early-goal Directed Automated Red Blood Cell Exchange for Acute Chest Syndrome in Sickle Cell Disease
Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
Validation of a Predictive Score of Acute Chest Syndrome
Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin
Utility of the Cardiac Electrical BiomarkerDisease
Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome
Bi-Level Positive Airway Ventilation for Acute Chest Syndrome
sPLA2 in EBC During Acute Chest Syndrome
A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial